[go: up one dir, main page]

PH12016501175B1 - Formulations of deoxycholic acid and salts thereof - Google Patents

Formulations of deoxycholic acid and salts thereof

Info

Publication number
PH12016501175B1
PH12016501175B1 PH12016501175A PH12016501175A PH12016501175B1 PH 12016501175 B1 PH12016501175 B1 PH 12016501175B1 PH 12016501175 A PH12016501175 A PH 12016501175A PH 12016501175 A PH12016501175 A PH 12016501175A PH 12016501175 B1 PH12016501175 B1 PH 12016501175B1
Authority
PH
Philippines
Prior art keywords
deoxycholic acid
pcnt
formulations
salts
composition
Prior art date
Application number
PH12016501175A
Other versions
PH12016501175A1 (en
Inventor
Robert Emil Hodge
Jeffrey Douglas Webster
Robert M Moriarty
Original Assignee
Allergan Sales Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45569726&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PH12016501175(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Sales Llc filed Critical Allergan Sales Llc
Publication of PH12016501175B1 publication Critical patent/PH12016501175B1/en
Publication of PH12016501175A1 publication Critical patent/PH12016501175A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)

Abstract

The present application is directed to an aqueous pharmaceutical composition comprising from about 0.4 pcnt w/v to less than about 2 pcnt w/v of a salt of deoxycholic acid, wherein the composition is maintained at a pH from about 8.1 to about 8.5 such that the composition is stabilized against precipitation. Also disclosed herein, are methods for stabilizing an aqueous pharmaceutical composition comprising from about 0.4 pcnt w/v to less than about 2 pcnt w/v of a salt of deoxycholic acid against precipitation, said method comprising maintaining pH of the solution from about 8.1 to about 8.5.
PH12016501175A 2011-08-23 2016-06-16 Formulations of deoxycholic acid and salts thereof PH12016501175A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2011/048806 WO2013028177A1 (en) 2011-08-23 2011-08-23 Formulations of deoxycholic acid and salts thereof

Publications (2)

Publication Number Publication Date
PH12016501175B1 true PH12016501175B1 (en) 2017-12-11
PH12016501175A1 PH12016501175A1 (en) 2017-12-11

Family

ID=45569726

Family Applications (2)

Application Number Title Priority Date Filing Date
PH1/2014/500240A PH12014500240A1 (en) 2011-08-23 2011-08-23 Formulations of deoxycholic acid and salts thereof
PH12016501175A PH12016501175A1 (en) 2011-08-23 2016-06-16 Formulations of deoxycholic acid and salts thereof

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PH1/2014/500240A PH12014500240A1 (en) 2011-08-23 2011-08-23 Formulations of deoxycholic acid and salts thereof

Country Status (18)

Country Link
JP (1) JP5919597B2 (en)
KR (5) KR102034606B1 (en)
CN (3) CN103826608A (en)
AU (3) AU2011375432B2 (en)
BR (1) BR112014000547B1 (en)
CA (1) CA2842177C (en)
CR (1) CR20140053A (en)
EA (1) EA029305B1 (en)
IL (1) IL230547A (en)
IN (1) IN2014CN02188A (en)
MX (1) MX350390B (en)
MY (1) MY184277A (en)
NZ (1) NZ620040A (en)
PH (2) PH12014500240A1 (en)
SG (1) SG2014013205A (en)
UA (1) UA113522C2 (en)
WO (1) WO2013028177A1 (en)
ZA (1) ZA201401027B (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8101593B2 (en) 2009-03-03 2012-01-24 Kythera Biopharmaceuticals, Inc. Formulations of deoxycholic acid and salts thereof
US20120237492A1 (en) 2011-02-18 2012-09-20 Kythera Biopharmaceuticals, Inc. Treatment of submental fat
KR20180100309A (en) * 2015-11-04 2018-09-10 키쎄라 바이오파마슈티컬즈 인코포레이티드 Methods for the treatment of accumulated fats using deoxycholic acid and its salts
KR101841193B1 (en) * 2016-09-22 2018-03-22 이경락 Composition for hypotonic lipolysis and manufacturing method thereof
US20180078621A1 (en) * 2016-09-22 2018-03-22 Kyoung Lack Lee Composition for hypotonic lipolysis and manufacturing method thereof
US20190314388A1 (en) * 2018-04-16 2019-10-17 Penmix Ltd. Pharmaceutical composition containing deoxycholic acid
KR102172439B1 (en) 2018-12-05 2020-10-30 송미희 Composition for lipolysis and injection composition comprising the same
KR102064864B1 (en) 2019-02-08 2020-01-10 (주)제테마 Topical injectable composition
KR102111346B1 (en) * 2019-08-20 2020-05-22 아영창 Aqueous composition with sodium deoxycholate having improved stability against precipitation
KR20220026068A (en) 2020-08-25 2022-03-04 강명범 Composition for lipolysis and injection composition comprising the same
CN116617160A (en) * 2023-07-25 2023-08-22 山东则正医药技术有限公司 Aqueous suspension, preparation method, freeze-dried powder, application and fat reduction injection
CN118005707A (en) * 2024-01-18 2024-05-10 山东省食品药品检验研究院 Sodium deoxycholate crystal form A and its preparation method and application

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2754709B1 (en) 1996-10-23 1999-03-05 Sanofi Sa COSMETIC COMPOSITION CONTAINING AN ANTAGONIST OF GAMMA NEUROPEPTIDE RECEPTORS AND ALPHA 2 ANTAGONISTS THAT MAY BE INCORPORATED IN SUCH A COMPOSITION
ATE292956T1 (en) * 1998-07-24 2005-04-15 Seo Hong Yoo CLEAR AQUEOUS SOLUTIONS CONTAINING BALE ACIDS
US6417179B1 (en) * 1998-10-13 2002-07-09 Craig G. Burkhart Ear wax solution
US20050048126A1 (en) * 2000-12-22 2005-03-03 Barrett Rabinow Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug
DE10361067A1 (en) * 2003-12-22 2005-07-14 Aventis Pharma Deutschland Gmbh Medicinal lipolysis of fat accumulations
US20060127468A1 (en) * 2004-05-19 2006-06-15 Kolodney Michael S Methods and related compositions for reduction of fat and skin tightening
US7754230B2 (en) 2004-05-19 2010-07-13 The Regents Of The University Of California Methods and related compositions for reduction of fat
PL2422789T3 (en) 2004-05-19 2018-09-28 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Injectable coposition comprising sodium deoxycholate
CA2610022A1 (en) 2005-06-06 2006-12-14 Georgetown University Compositions and methods for lipo modeling
TW201011755A (en) 2008-09-10 2010-03-16 Skymedi Corp Flash memory system and its data recovery method
JP5420946B2 (en) * 2009-03-23 2014-02-19 富士フイルム株式会社 Minoxidil aqueous composition containing bile acids
EP2645099A1 (en) 2012-03-30 2013-10-02 Phares Pharmaceutical Research N.V. Biorelevant compositions

Also Published As

Publication number Publication date
KR20170075016A (en) 2017-06-30
KR101751585B1 (en) 2017-06-27
SG2014013205A (en) 2014-05-29
KR20200013103A (en) 2020-02-05
CR20140053A (en) 2014-06-12
MX350390B (en) 2017-09-06
KR20190119677A (en) 2019-10-22
WO2013028177A1 (en) 2013-02-28
PH12014500240A1 (en) 2022-11-23
AU2018202807A1 (en) 2018-05-10
CA2842177C (en) 2016-07-19
KR20150000448A (en) 2015-01-02
IL230547A0 (en) 2014-03-31
BR112014000547B1 (en) 2021-11-09
AU2016202661A1 (en) 2016-05-19
AU2011375432B2 (en) 2016-02-04
KR20180123734A (en) 2018-11-19
NZ620040A (en) 2016-06-24
EA029305B1 (en) 2018-03-30
AU2011375432A1 (en) 2014-02-06
AU2016202661B2 (en) 2018-02-22
CN108619089A (en) 2018-10-09
MX2014001495A (en) 2014-04-25
EA201490175A1 (en) 2014-06-30
KR102034606B1 (en) 2019-10-22
CN108743522A (en) 2018-11-06
AU2018202807B2 (en) 2020-01-16
IL230547A (en) 2017-02-28
UA113522C2 (en) 2017-02-10
JP5919597B2 (en) 2016-05-18
MY184277A (en) 2021-03-30
BR112014000547A2 (en) 2017-02-14
KR101919269B1 (en) 2018-11-15
KR102073536B1 (en) 2020-02-04
CA2842177A1 (en) 2013-02-28
PH12016501175A1 (en) 2017-12-11
JP2014524467A (en) 2014-09-22
ZA201401027B (en) 2017-09-27
IN2014CN02188A (en) 2015-05-29
CN103826608A (en) 2014-05-28

Similar Documents

Publication Publication Date Title
PH12016501175B1 (en) Formulations of deoxycholic acid and salts thereof
EA201590371A1 (en) 1,4-DESIGNED PYRIDAZIN ANALOGUES AND METHODS OF TREATMENT RELATED TO SMN DEFICIENCY CONDITIONS
MY160249A (en) Fatty acid fumarate derivatives and their uses
UA105229C2 (en) Pharmaceutical formulation
MX340125B (en) Storage-stable 2-hydroxy-4-(methylthio) butyric acid nitrile.
MX2013010046A (en) Parenteral administration of tapentadol.
WO2012095667A3 (en) Improvements in coating technology
MX348977B (en) Preparation of bicyclic guanidine salts in an aqueous media.
MY171414A (en) Compositions and methods for improving the compatibility of water soluble herbicide salts
MX2009007265A (en) Salts, aqueous liquid compositions containing salts of s-(+)-abscisic acid and methods of their preparation.
CY1115372T1 (en) DOSOXYLIC ACID COMPOSITIONS AND ITS SALTS
EA201890018A1 (en) COMPOSITION FOR ATTACHING HAIR FORM
MX348979B (en) Plant disease control agent.
BR112016027760A2 (en) low ph synthesis method of zinc-lysine complex
CA2922375C (en) Alpha-tea salt forms: compositions and uses for treating disease
PH12015502717B1 (en) Anti-fibrogenic compounds, methods and uses thereof
NZ613554A (en) Caprylate viral deactivation
MX2017002790A (en) Salt of cephalosporin derivative, crystalline solid form of same and method for producing same.
PH12018501046A1 (en) Crystals of monovalent cation salt of 3-hydroxyisovaleric acid, and method for producing said crystals
EA201992511A1 (en) COMPOSITIONS OF DESOXYCHOLIC ACID AND ITS SALTS
PH12013500945A1 (en) Crystalline forms of an alkoxymidazol-1-ylmethyl-biphenyl carboxylic acid
EA201790055A3 (en) COMPOSITIONS OF DEOXIC ACID AND ITS SALTS
FR2975992B1 (en) PROCESS FOR THE PREPARATION OF A FLUOROMETHYLPYRAZOLE COMPOUND IN CARBOXYLIC ACID OR DERIVED FORM
JP2016204285A5 (en)
WO2015050199A3 (en) Novel compound, production method therefor, and application therefor